Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elbasvir/grazoprevir plus sofosbuvir and ribavirin retreatment for chronic hepatitis C genotype 1 or 4 after NS5A inhibitor failure
2017-000432-34Phase 3Terminated
- Sponsor
- Fundación SEIMC-GeSIDA
- Start
- Apr 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of elbasvir, grazoprevir, sofosbuvir and ribavirin in chronic hepatitis C (CHC), sponsored by Fundación SEIMC-GeSIDA. Primary endpoint: SVR12 rate. Started Apr 2017; status: terminated.
02
Drugs
elbasvirgrazoprevirsofosbuvirribavirin
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on 2017-000432-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000432-34.